Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Early Diagnosis of Pancreatic Cancer-Network Collaborative Studies

Early Diagnosis of Pancreatic Cancer-Network Collaborative Studies

196
UNKNOWN
G.I. and Other Associated Cancers Research Group

Determining and quantifying the types of mucin core proteins to which CA19-9 is attached will result in assays with improved performance characteristics compared to CA19-9 alone.

Specific Aim 1) Utilize newly developed and to be developed antibodies against the mucin core proteins MUC1, MUC4, and MUC17 to develop an improved serum assay for pancreatic adenocarcinoma. Specific Aim 2) Develop and utilize a set of monoclonal antibodies that recognize serum forms of distinct mucin core proteins, utilize these to improve the diagnostic capability of the CA 19-9 type tests for nonmalignant, premalignant and malignant lesions of the pancreas, and evaluate the capability of the test to discriminate pancreatic cancer from other adenocarcinomas.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 03/06/2014

Thank you to everyone who helped make the 27th EDRN Steering Committee Meeting a success. We look forward to seeing everyone at the 9th EDRN Scientific Workshop from September 8-11, 2014 in Washington D.C.

Announcement